Dr. Garner joined Eli Lilly and Company in 1997 as a senior scientist where he led a laboratory investigating the drug metabolism, pharmacokinetics and pharmacodynamics of new chemical entities in animal models and humans. His work in these areas supported the advancement of many innovative molecules into human testing, late clinical development, and the commercialization of innovative new medicines treating schizophrenia and cancer. Dr. Garner subsequently served as senior director of project management and research strategy overseeing the development of more than 50 programs in discovery and development and providing portfolio strategy and management to Lilly Research Laboratories. Dr. Garner moved into regulatory sciences in 2011 where he led the North American regulatory affairs support of Lilly’s Biomedicines development and product portfolio across neuroscience, musculoskeletal, urology, men’s health, cardiovascular, and immunology diseases, where his team brought a number of NMEs and NBE to market and supported the broad portfolio of marketed products. In his current role, Dr. Garner currently leads the global regulatory function for Eli Lilly and Company supporting discovery, development, medical devices, all human health business units, and global manufacturing. Dr. Garner has published numerous scientific articles on his research and in health policy and has been invited to provide national and international lectures on his research, drug discovery, drug development and regulatory sciences.